Leshem B, Gotsman B, Kedar E
Cancer Immunol Immunother. 1984;17(2):117-23. doi: 10.1007/BF00200047.
The murine lymphoma (thymoma) PIR-2 of C57BL/6 origin, primarily induced in our laboratory by fractionated X-ray irradiation, has been shown to be nonimmunogenic by its failure to immunize syngeneic mice in vivo or to evoke a cytotoxic response in primary mixed lymphocyte-tumor cell cultures (MLTC) in vitro. We were able, however, to demonstrate the existence of anti-PIR-2 cytotoxic cells among allogeneic-primed C57BL/6 responding lymphocytes using the technique of limiting dilution cultures (LDC). The frequency of anti-PIR-2 cytotoxic cells among C57BL/6 lymphocytes sensitized against BALB/c splenocytes in mixed leukocyte culture (MLC) was 1/20 to 1/40, and the cytotoxic activity of positive LDC wells against PIR-2 reached 60% as determined by a 4-h 51Cr-release assay. The frequency of anti-PIR-2 cytotoxic cells could be increased two- to 10-fold (up to 1/4) by removing nylon-wool-adherent cells from the primed cell population and/or by enriching the primed lymphoblast population on a Percoll density gradient. Anti-PIR-2 cytotoxic cells were found to be Thy1+; Lyt1-2+ cells. Clones isolated from the LDC wells manifested strong cytotoxic activity toward PIR-2 cells and the stimulating BALB/c splenocytes but not against other H-2b tumor lines or C57BL/6 splenocytes. We suggest that the procedure of allostimulation in MLC-LDC is an effective in vitro means of generating highly reactive cytotoxic cells against poorly immunogenic neoplasms.
源自C57BL/6的鼠淋巴瘤(胸腺瘤)PIR-2最初由我们实验室通过分次X射线照射诱导产生,已证明其无免疫原性,因为它无法在体内使同基因小鼠产生免疫,也不能在体外原代混合淋巴细胞 - 肿瘤细胞培养物(MLTC)中引发细胞毒性反应。然而,我们能够使用有限稀释培养(LDC)技术在同种异体致敏的C57BL/6反应性淋巴细胞中证明抗PIR-2细胞毒性细胞的存在。在混合白细胞培养(MLC)中针对BALB/c脾细胞致敏的C57BL/6淋巴细胞中,抗PIR-2细胞毒性细胞的频率为1/20至1/40,通过4小时51Cr释放试验测定,阳性LDC孔对PIR-2的细胞毒性活性达到60%。通过从致敏细胞群体中去除尼龙毛粘附细胞和/或通过在Percoll密度梯度上富集致敏淋巴母细胞群体,抗PIR-2细胞毒性细胞的频率可增加2至10倍(高达1/4)。发现抗PIR-2细胞毒性细胞为Thy1+;Lyt1-2+细胞。从LDC孔中分离的克隆对PIR-2细胞和刺激的BALB/c脾细胞表现出强烈的细胞毒性活性,但对其他H-2b肿瘤系或C57BL/6脾细胞无细胞毒性。我们认为MLC-LDC中的同种异体刺激程序是一种在体外产生针对低免疫原性肿瘤的高反应性细胞毒性细胞的有效方法。